The use of exogenous IL-22 after transplantation is supported by the findings that host-derived IL-22–producing lymphocytes are eliminated by the donor’s immune system in GVHD (34, 46, 47) and that CS suppress IL-22 production in PBMCs (48). This evidence concerns the gene IL22 and graft versus host disease.